{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:32:15Z","timestamp":1790548335119,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Datopotamab deruxtecan (Dato-DXd) is an investigational antibody\u2013drug conjugate that has shown promising results in phase III clinical trials of lung and breast cancers. Stomatitis is a common adverse event associated with Dato-DXd in these trials, and there are currently no formalized guidelines for its prevention and management. An expert consensus was needed to establish these guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fifteen experts participated in a modified three-round Delphi to achieve consensus on the prevention and management of Dato-DXd-related stomatitis in lung and breast cancer patients. Fourteen experts had managed Dato-DXd-induced stomatitis and served as investigators in the TROPION-Lung01, TROPION-Lung05, and TROPION-Breast01 phase III clinical trials. The first two rounds consisted of anonymized surveys with a mixture of open- and closed-ended questions, and the third round consisted of a consensus group meeting and 1:1 follow-up meetings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>Experts recognized stomatitis as an important adverse event associated with several anticancer treatments and its impact on patients\u2019 quality of life. Lung and breast cancer specialists noted similar manifestations of stomatitis with Dato-DXd, with breast cancer experts referencing similarities to everolimus-induced conditions and lung cancer experts reporting ulcerative lesions. There was consensus on the need for standardized guidelines to improve outcomes and reduce treatment disruptions. Agreed preventive measures emphasized patient education, oral hygiene, and prophylactic mouthwashes. Management strategies focused on patient-centered care, monitoring of symptoms, and timely interventions, such as the use of a steroid-containing mouthwash to maintain treatment schedules and quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation<\/jats:title>\n            <jats:p>We used the expert consensus to provide guidelines for the prevention and management of stomatitis in patients treated with Dato-DXd.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Putting research into context<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Evidence before this study<\/jats:title>\n            <jats:p>Dato-DXd has shown promising results in clinical trials for lung and breast cancers. However, many patients in these trials developed stomatitis, an adverse event that may impact quality of life and disrupt treatment regimens. The lack of standardized guidelines for dealing with stomatitis in this context necessitated the establishment of best practices via expert consensus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Added value of this study<\/jats:title>\n            <jats:p>This study provides peer-reviewed guidance for the prevention and management of stomatitis secondary to Dato-DXd. Most experts selected for this study had experience using this therapy and preventing and managing stomatitis associated with Dato-DXd and other anticancer treatments. Thus, the study has collected the perspectives of well-placed, expert clinicians and derived best practices pending the completion of clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Implications of all the available evidence<\/jats:title>\n            <jats:p>The development and implementation of this guidance and the education therein will lead to improved quality of life, greater treatment compliance, and better clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09805-y","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T09:45:35Z","timestamp":1754387135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan"],"prefix":"10.1007","volume":"33","author":[{"given":"Hope","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora S.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Ernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Treister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"9805_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720","volume":"125","author":"RS Heist","year":"2024","unstructured":"Heist RS, Sands J, Bardia A et al (2024) Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 125:102720","journal-title":"Cancer Treat Rev"},{"key":"9805_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/annonc\/mdv595","volume":"27","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Hortobagyi GN, Yao J et al (2016) Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27:519\u2013525","journal-title":"Ann Oncol"},{"key":"9805_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-020-01715-7","volume":"39","author":"C Pulito","year":"2020","unstructured":"Pulito C, Cristaudo A, Porta CL et al (2020) Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 39:210","journal-title":"J Exp Clin Cancer Res"},{"key":"9805_CR4","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.2147\/JIR.S427336","volume":"16","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Chen X, Sun Z, Shen X, Huang Y, Liu J (2023) Toxic epidermal necrolysis and Stevens-Johnson syndrome following sintilimab administration in a non-small cell lung cancer patient: a case report. J Inflamm Res 16:5061\u20135067","journal-title":"J Inflamm Res"},{"key":"9805_CR5","doi-asserted-by":"crossref","unstructured":"Suzuki A (2022) Management of cancer treatment-induced oral mucositis. In: Tomita H (ed) Inflammation and Oral Cancer, Academic Press, p 183\u201397","DOI":"10.1016\/B978-0-323-88526-3.00010-5"},{"key":"9805_CR6","first-page":"807","volume":"17","author":"MH Lederhandler","year":"2018","unstructured":"Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN, Lo SK (2018) Severe oral mucositis: a rare adverse event of pembrolizumab. J Drugs Dermatol 17:807\u2013809","journal-title":"J Drugs Dermatol"},{"key":"9805_CR7","doi-asserted-by":"crossref","unstructured":"Nicolatou-Galitis O, Bossi P, Orlandi E, Ren\u00e9-Jean Bensadoun null (2021) The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. Support Care Cancer 29:5701\u20139","DOI":"10.1007\/s00520-021-06048-5"},{"key":"9805_CR8","first-page":"985","volume":"18","author":"RV Lalla","year":"2010","unstructured":"Lalla RV, Latortue MC, Hong CH et al (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18:985\u2013992","journal-title":"Support Care Cancer"},{"key":"9805_CR9","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.21037\/tcr.2020.02.77","volume":"9","author":"AHM Al-Rudayni","year":"2020","unstructured":"Al-Rudayni AHM, Gopinath D, Maharajan MK, Menon RK (2020) Impact of oral mucositis on quality of life in patients undergoing oncological treatment: a systematic review. Transl Cancer Res 9:3126\u20133134","journal-title":"Transl Cancer Res"},{"key":"9805_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fphar.2017.00354","volume":"8","author":"M Cinausero","year":"2017","unstructured":"Cinausero M, Aprile G, Ermacora P et al (2017) New Frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front Pharmacol 8:354","journal-title":"Front Pharmacol"},{"key":"9805_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/fon-2023-0188","volume":"20","author":"A Bardia","year":"2024","unstructured":"Bardia A, Jhaveri K, Kalinsky K et al (2024) TROPION-Breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+\/HER2- breast cancer. Future Oncol 20:423\u2013436","journal-title":"Future Oncol"},{"key":"9805_CR12","doi-asserted-by":"publisher","first-page":"S1665","DOI":"10.1016\/j.annonc.2023.10.588","volume":"34","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Lisberg AE, Paz-Ares L et al (2023) 509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. Ann Oncol 34:S1665\u2013S1666","journal-title":"Ann Oncol"},{"key":"9805_CR13","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L et al (2024) Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study. J Clin Oncol 43(3):260\u2013272. Accessed 20\u00a0Jan 2025"},{"key":"9805_CR14","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1016\/j.annonc.2023.09.2348","volume":"34","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Ahn M-J, Lisberg AE et al (2023) 1314MO TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Ann Oncol 34:S755\u2013S756","journal-title":"Ann Oncol"},{"key":"9805_CR15","unstructured":"Bardia A, Jhaveri K, Im SA et al (2024) Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol 43(3):285\u2013296. Accessed 20 Jan 2025"},{"key":"9805_CR16","doi-asserted-by":"crossref","unstructured":"Jhaveri K. LBA2 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable\/metastatic HR+\/HER2\u2013 breast cancer (BC): additional safety analysis from TROPION-Breast01. 2024; published online May 16. https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-breast-cancer-2024\/datopotamab-deruxtecan-dato-dxd-vs-chemotherapy-ct-in-pretreated-inoperable-metastatic-hr-her2-breast-cancer-bc-additional-safety-analysi (accessed Aug 27, 2024).","DOI":"10.1016\/j.esmoop.2024.103479"},{"key":"9805_CR17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT et al (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18:654\u2013662","journal-title":"Lancet Oncol"},{"key":"9805_CR18","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV et al (2020) MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126:4423\u20134431","journal-title":"Cancer"},{"key":"9805_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.28592","volume":"120","author":"RV Lalla","year":"2014","unstructured":"Lalla RV, Bowen J, Barasch A et al (2014) MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453\u20131461","journal-title":"Cancer"},{"key":"9805_CR20","doi-asserted-by":"crossref","unstructured":"Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, ESMO Guidelines Committee (2015) Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol\u00a026 (Suppl 5): v139\u2013151","DOI":"10.1093\/annonc\/mdv202"},{"key":"9805_CR21","doi-asserted-by":"publisher","unstructured":"Abdalla-Aslan R, Bonomo P, Keefe D\u00a0et al (2024) Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine\u00a073. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102675.","DOI":"10.1016\/j.eclinm.2024.102675"},{"key":"9805_CR22","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32:1008\u20131015","journal-title":"J Adv Nurs"},{"key":"9805_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jgo.2019.03.012","volume":"10","author":"MDL Alarc\u00f3n","year":"2019","unstructured":"Alarc\u00f3n MDL, Est\u00e9vez FV, Cabez\u00f3n-Guti\u00e9rrez L et al (2019) Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study J Geriatr Oncol 10:643\u2013652","journal-title":"A Delphi study J Geriatr Oncol"},{"key":"9805_CR24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3109\/0284186X.2010.506884","volume":"49","author":"V Valentini","year":"2010","unstructured":"Valentini V, Glimelius B (2010) Rectal cancer radiotherapy: towards European consensus. Acta Oncol 49:1206\u20131216","journal-title":"Acta Oncol"},{"key":"9805_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.critrevonc.2016.01.010","volume":"100","author":"V De Sanctis","year":"2016","unstructured":"De Sanctis V, Bossi P, Sanguineti G et al (2016) Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit Rev Oncol Hematol 100:147\u2013166","journal-title":"Crit Rev Oncol Hematol"},{"key":"9805_CR26","doi-asserted-by":"publisher","first-page":"107327482211193","DOI":"10.1177\/10732748221119354","volume":"29","author":"C Lynch","year":"2022","unstructured":"Lynch C, Harrison S, Butler J et al (2022) An international consensus on actions to improve lung cancer survival: a modified delphi method among clinical experts in the international cancer benchmarking partnership. Cancer Control 29:10732748221119354","journal-title":"Cancer Control"},{"key":"9805_CR27","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.3390\/ijms24055058","volume":"24","author":"M Lambros","year":"2023","unstructured":"Lambros M, Moreno J, Fei Q, Parsa C, Orlando R, Van Haute L (2023) Transcriptome sequencing reveals the mechanism behind chemically induced oral mucositis in a 3D cell culture model. Int J Mol Sci 24:5058","journal-title":"Int J Mol Sci"},{"key":"9805_CR28","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2147\/OTT.S96899","volume":"9","author":"Y Kwon","year":"2016","unstructured":"Kwon Y (2016) Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. Onco Targets Ther 9:2007\u20132016","journal-title":"Onco Targets Ther"},{"key":"9805_CR29","doi-asserted-by":"crossref","unstructured":"Wray RH, Piault E, Miller-Potucka L et al (2023) Abstract LB143: improving treatment outcomes: a digital solution for remote patient monitoring of stomatitis for patients receiving Dato-DXd. Cancer Res\u00a083:LB143","DOI":"10.1158\/1538-7445.AM2023-LB143"},{"key":"9805_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1191\/1078155205jp166oa","volume":"11","author":"A Chan","year":"2005","unstructured":"Chan A, Ignoffo RJ (2005) Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract 11:139\u2013143","journal-title":"J Oncol Pharm Pract"},{"key":"9805_CR31","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/nutrit\/nuac105","volume":"81","author":"R Amiri Khosroshahi","year":"2023","unstructured":"Amiri Khosroshahi R, Talebi S, Zeraattalab-Motlagh S et al (2023) Nutritional interventions for the prevention and treatment of cancer therapy-induced oral mucositis: an umbrella review of systematic reviews and meta-analysis. Nutr Rev 81:1200\u20131212","journal-title":"Nutr Rev"},{"key":"9805_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.adaj.2017.10.024","volume":"149","author":"MS Chambers","year":"2018","unstructured":"Chambers MS, Rugo HS, Litton JK, Meiller TF (2018) Stomatitis associated with mammalian target of rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc 149:291\u2013298","journal-title":"J Am Dent Assoc"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09805-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T02:56:37Z","timestamp":1758164197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09805-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9805"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09805-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"All participants in this modified Delphi study provided informed consent prior to participation. The study\u2019s purpose and approach (as described in the Methods section) were clearly explained including the iterative nature of the Delphi method. The estimated time commitment was agreed with all participants. All participants were informed that their responses would remain confidential, and that data would be reported in an aggregated manner to ensure anonymity. Participation was entirely voluntary, and individuals were free to withdraw at any stage of the study without penalty. All participants were made aware of the funding source prior to providing consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"756"}}